Live Analyst Rating Changes 24938 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Sami Corwin
WB

Sami Corwin

Wall Street Analyst
★★★☆☆
#1160
on 13Foresight · ranked by our own returns
60%
Success Rate
+20.5%
Average Return
29 of 48 calls profitable · +15.2% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 60% of Sami Corwin's ratings turned a profit when each position was held for 1 year — averaging +20.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

129 Buy 26 Hold 0 Sell
Sami's Stock Coverage 23 ratings · 2026-08-14
Company Date Position Consensus Price Target 1-Yr Return vs S&P 500
CABA
Cabaletta Bio
Aug 13, 2026 BUY Strong Buy
+413.0% avg upside
16 analysts
+1.5% ·
ALLO
Allogene Therapeutics
Aug 13, 2026 BUY Strong Buy
+667.0% avg upside
28 analysts
+3.5% ·
KYTX
Kyverna Therapeutics, Inc.
Aug 12, 2026 BUY Strong Buy
+238.1% avg upside
7 analysts
+1.5% ·
NGNE
Neurogene
Aug 11, 2026 BUY Buy
+36.2% avg upside
23 analysts
-2.3% ·
ZVRA
Zevra Therapeutics
Aug 06, 2026 BUY Strong Buy
+95.5% avg upside
15 analysts
-4.7% ·
TNYA
Tenaya Therapeutics
Aug 06, 2026 BUY Strong Buy
+1263.8% avg upside
11 analysts
+0.0% ·
SLDB
Solid Biosciences
Aug 06, 2026 BUY Strong Buy
+74.4% avg upside
23 analysts
+5.6% ·
TYRA
Tyra Bioscience
Aug 05, 2026 BUY Strong Buy
+77.8% avg upside
17 analysts
-1.6% ·
CRSP
Crispr Therapeutics AG
Aug 04, 2026 BUY Buy
+40.1% avg upside
41 analysts
+0.9% ·
BEAM
Beam Therapeutics
Aug 04, 2026 BUY Strong Buy
+96.3% avg upside
25 analysts
-5.6% ·
KRYS
Krystal Biotech
Aug 03, 2026 BUY Strong Buy
-21.7% avg upside
19 analysts
+6.3% ·
AKTS
Aktis Oncology, Inc.
May 02, 2026 BUY Strong Buy
+33.9% avg upside
9 analysts
$18.75
21.11% Downside
+27.0% ·
SRPT
Sarepta Therapeutics
Feb 26, 2026 HOLD Buy
+223.8% avg upside
49 analysts
+3.7% ·
RCKT
Rocket Pharmaceuticals
Feb 26, 2026 BUY Buy
+397.3% avg upside
29 analysts
-23.4% ·
BMRN
BioMarin Pharmaceutical
Feb 24, 2026 HOLD Strong Buy
+38.4% avg upside
52 analysts
+7.6% ·
PTCT
PTC Therapeutics
Feb 20, 2026 BUY Strong Buy
+12.5% avg upside
29 analysts
+1.5% ·
RARE
Ultragenyx Pharmaceutical
Feb 13, 2026 BUY Strong Buy
+151.9% avg upside
36 analysts
+29.1% ·
QURE
uniQure
Feb 06, 2026 HOLD Strong Buy
+26.1% avg upside
29 analysts
+89.5% ·
LEGN
Legend Biotech
Nov 12, 2025 HOLD Strong Buy
+206.4% avg upside
27 analysts
-34.6% ·
NKTX
Nkarta
Nov 11, 2025 HOLD Strong Buy
+700.6% avg upside
16 analysts
+15.9% ·
IPSC
Century Therapeutics
Aug 29, 2025 HOLD Strong Buy
+174.9% avg upside
11 analysts
+291.8% ·
MESO
Mesoblast
Dec 22, 2023 HOLD Strong Buy
+50.8% avg upside
14 analysts
+577.3% ·
TSHA
Taysha Gene Therapies
Feb 01, 2023 BUY Strong Buy
+129.9% avg upside
21 analysts
+28.9% ·
🔒 18 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Sami Corwin — Frequently Asked Questions
How accurate are Sami Corwin's stock ratings?
Based on the calls 13Foresight could measure, about 52% of Sami's ratings were profitable over a one-year hold, with an average return of +19.8% per rating, or +15.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Sami ranked on 13Foresight?
Sami Corwin is currently ranked #1160 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Sami cover?
Sami most recently has ratings on CABA, ALLO, KYTX, NGNE, ZVRA, TNYA, SLDB, TYRA, CRSP, BEAM, KRYS, AKTS and 11 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.